Analysts expect Natera Inc (NASDAQ:NTRA) to announce $67.03 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Natera’s earnings, with estimates ranging from $66.70 million to $67.71 million. Natera reported sales of $63.07 million during the same quarter last year, which indicates a positive year over year growth rate of 6.3%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, August 14th.
According to Zacks, analysts expect that Natera will report full-year sales of $288.47 million for the current financial year, with estimates ranging from $284.94 million to $291.55 million. For the next fiscal year, analysts forecast that the business will report sales of $357.77 million, with estimates ranging from $322.33 million to $398.36 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Natera.
Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.05. The business had revenue of $66.82 million during the quarter, compared to analyst estimates of $66.40 million. Natera had a negative net margin of 49.33% and a negative return on equity of 699.31%.
Shares of Natera stock opened at $262,138,000.00 on Friday. The company has a market cap of $1.90 billion, a P/E ratio of -121,924,651.16 and a beta of 1.43. The company has a debt-to-equity ratio of 20.88, a current ratio of 1.85 and a quick ratio of 1.73. The business has a fifty day moving average price of $23.76. Natera has a fifty-two week low of $11.08 and a fifty-two week high of $29.62.
In related news, Chairman Matthew Rabinowitz sold 1,418 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $24.79, for a total value of $35,152.22. Following the completion of the sale, the chairman now owns 1,286,612 shares in the company, valued at approximately $31,895,111.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Jonathan Sheena sold 1,033 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $24.79, for a total transaction of $25,608.07. Following the completion of the sale, the insider now owns 240,061 shares of the company’s stock, valued at approximately $5,951,112.19. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,771 shares of company stock valued at $140,742. 9.29% of the stock is owned by insiders.
Institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC raised its position in Natera by 47.2% during the 4th quarter. Squarepoint Ops LLC now owns 149,160 shares of the medical research company’s stock worth $2,082,000 after buying an additional 47,860 shares during the last quarter. Perkins Capital Management Inc. raised its position in Natera by 121.3% during the 1st quarter. Perkins Capital Management Inc. now owns 129,900 shares of the medical research company’s stock worth $2,679,000 after buying an additional 71,200 shares during the last quarter. RMB Capital Management LLC purchased a new position in Natera during the 4th quarter worth $1,017,000. Principal Financial Group Inc. raised its position in Natera by 60.3% during the 4th quarter. Principal Financial Group Inc. now owns 233,205 shares of the medical research company’s stock worth $3,255,000 after buying an additional 87,750 shares during the last quarter. Finally, Citigroup Inc. raised its position in Natera by 930.0% during the 4th quarter. Citigroup Inc. now owns 193,618 shares of the medical research company’s stock worth $2,703,000 after buying an additional 174,821 shares during the last quarter. Institutional investors own 80.27% of the company’s stock.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
See Also: Find a Trading Strategy That Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.